MEDS · Terminates IP acquisition LOI

DataMeds AI terminated its Second Amended and Restated Letter of Intent with multiple counterparties for the in-license or acquisition of IP in exchange for common stock, citing market conditions. No fees or obligations are owed, and no shares will be issued under the terminated LOI. Existing license agreements with REBOOT and Datavault remain in effect.

• LOI terminated effective November 3, 2026, due to market conditions.
• No fees or obligations owed by DataMeds as a result of termination.
• No shares will be issued in connection with the terminated LOI.
• Exclusive license with REBOOT for GLP-1 user management remains in effect.